AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Asthma and Antibiotic Use May Predict Nasal Polyp Recurrence After Endoscopic Sinus Surgery Feb. 4, 2025 — The probability of revision sinus surgery including the removal of nasal polyps is ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

As one of our resident wardrobe-basics experts, I’ve learned that a good white T-shirt is easy to find, but a truly great one — one that hits the marks on comfort and durability as well as ...

A 48-year-old woman reported a 1-year history of breathlessness, persistent cough and recurrent chest infections. She was a former smoker with a medical history of nasal polyps and asthma since ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...

Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research.

with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP ... number of blood eosinophils (a type of white blood cell that may contribute to your ...